Regulatory tailwinds like Institutional participation, Indices and tie-up with Retail bank subsidiaries can boost trading volumes further and increase depth in the long run. Globally Institutional clients account for ~50% of the total derivatives volumes. We continue to remain constructive on the long-term growth opportunities and the concern related to increase in competition is behind us. There has been no impact of the whistle-blower letter and the physical delivery mechanism remains robust. We estimate revenue/PAT CAGR of 19/22% over FY19-22E. We see value in MCX based on (1) Embedded non-linearity, (2) ADTV growth, (3) Market leadership and (4) Net cash of Rs 14bn (~28% of Mcap). Risks include regulatory delays, increase in competition and drop in Bullion volumes and commodity volatility. We maintain BUY on MCX based on in-line revenue and margin beat in 2QFY20. Market share (94%) is increasing despite rise in competition. Embedded non-linearity and cost control is leading to margin expansion. We assign 30x to core Sep 21 PAT and add net cash (20% discount) to arrive at SoTP of Rs 1,175 (16% upside).